Rational design of new tumoractivated(TM) cytotoxic agents

Oncology

Volumn 57, Issue SUPPL. 1, 1999, Pages 9-15

  Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

5 Fluorouracil; Fluoropyrimidines; Oral chemotherapy; Solid tumors; Tumor selective activation; Xeloda (capecitabine)

Indexed keywords

CAPECITABINE; CARBOXYLESTERASE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTIDINE DEAMINASE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; THYMIDINE PHOSPHORYLASE;

BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DRUG ABSORPTION; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TUMOR LEVEL; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS;

EID: 0032807766     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055263     Document Type: Review

References (14)

1. Miwa M, Ura M, Nihida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishisuka H: Design of an oral fluoropyrimidine carbonate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;1274-1281.
2. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58/4:685-690
3. Pinedo HM, Peters GF: Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
4. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H; Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4/4:1013-1019.
5. 4-pentoxyloxycarbonyl-5′-DFCR. Proc Jpn Cancer Assoc (abstr) 1994; 2410.
6. Ishikawa T, Fukase Y, Yamamoto T, Ishitsuka H: Jpn Soc Cancer Ther 1995;30:8.
7. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
8. Sawada N, Ishikawa T, Yoshikubo T, Nishida M, Ishitsuka H: Jpn Soc Cancer Ther 1996;31: 722.
9. Ishikawa T, Utoh M, Sawada N, Sekiguchi F, Ishitsuka H: Xeloda™ (capecitabine): An orally available tumor-selective fluoropyrimidine carbamate. Proc Am Soc Clin Oncol 1997;16: 208a (abstract 727).
10. Beale P, Aherne W, Judson I, Trigo J, Wolf L, Walker R, Crompton T, Yin H, Mulligan T, Jones D, Reigner BG: Excretion balance and pharmacokinetic study of Xeloda™ in cancer patients. Ann Oncol 1998;9 (suppl 2): 119.
11. Reigner BG, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998; 4:941-948.
12. Reigner BG, Glynne Jones R, Cassidy J, Schuller J, Goggin T, Jones D, Twelves C: Hepatic dysfunction due to liver metastasis does not affect the bioactivation of Xeloda™. Proc Am Soc Clin Oncol 1998;17:224a (abstract 863).
13. Schuller J, Cassidy J, Reigner BG, Roos B, Pietrzak C, Springer B, Ishitsuka H, Dumont E: Tumor selective activation of Capecitabine in colorectal cancer patients. Onkologie 1997;20 suppl 1 (abstract 732).
14. Kovach JS, Beart RW: Cellular pharmacology of fluorinated pyrimidines in vivo in man. Invest New Drugs 1989;7:13-25.